4//SEC Filing
ODONNELL FRANCIS E JR 4
Accession 0001103021-20-000052
CIK 0001103021other
Filed
Mar 17, 8:00 PM ET
Accepted
Mar 18, 4:18 PM ET
Size
20.2 KB
Accession
0001103021-20-000052
Insider Transaction Report
Form 4
ODONNELL FRANCIS E JR
Director10% Owner
Transactions
- Award
Common Stock
2020-03-16+18,284→ 725,322 total - Award
Common Stock
2020-03-16+62,500→ 673,754 total - Exercise/Conversion
Restricted Stock Units
2020-03-16−62,500→ 0 totalExercise: $0.00Exp: 2020-03-19→ Common Stock (62,500 underlying) - Exercise/Conversion
Common Stock
2020-03-16+15,000→ 688,754 total - Sale
Common Stock
2020-03-16$3.60/sh−38,750$139,500→ 686,572 total - Exercise/Conversion
Common Stock
2020-03-16+62,500→ 611,254 total - Award
Common Stock
2020-03-16+15,000→ 700,470 total - Sale
Common Stock
2020-03-17$3.63/sh−30,500$110,715→ 656,072 total - Exercise/Conversion
Restricted Stock Units
2020-03-16−15,000→ 0 totalExercise: $0.00Exp: 2021-03-19→ Common Stock (15,000 underlying)
Footnotes (9)
- [F1]The shares of common stock were acquired by the Reporting Person as a result of the vesting of 62,500 Restricted Stock Units ("RSUs") granted to the Reporting Person on February 6, 2017 under the Issuer's 2011 Equity Incentive Plan, as amended, (the EIP).
- [F2]The shares of common stock were acquired by the Reporting Person as a result of the vesting of 62,500 Performance RSUs granted to the Reporting Person on February 6, 2017 under the EIP, subject to certain performance measures.
- [F3]The shares of common stock were acquired by the Reporting Person as a result of the vesting of 15,000 RSUs granted to the Reporting Person on February 18, 2018 under the EIP. The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2021.
- [F4]The shares of common stock were acquired by the Reporting Person as a result of the vesting of 15,000 Performance RSUs granted to the Reporting Person on February 18, 2018 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2021 subject to certain performance measures.
- [F5]The shares of Common Stock were acquired by the Reporting Person as a result of the vesting of 18,284 RSUs granted to the Reporting Person under the Issuer's Long-Term Incentive Plan.
- [F6]The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan.
- [F7]The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.
- [F8]On March 16, 2020, the Reporting Person sold an aggregate of 38,750 shares of the Issuer's Common Stock at a weighted average price of $3.60 per share. The highest sale price for the Common Stock was $3.72 per share and the lowest sale price was $3.46 per share.
- [F9]On March 17, 2020, the Reporting Person sold an aggregate of 30,500 shares of the Issuer's Common Stock at a weighted average price of $3.63 per share. The highest sale price for the Common Stock was $3.81 per share and the lowest sale price was $3.39 per share.
Documents
Issuer
BIODELIVERY SCIENCES INTERNATIONAL INC
CIK 0001103021
Entity typeother
Related Parties
1- filerCIK 0001066040
Filing Metadata
- Form type
- 4
- Filed
- Mar 17, 8:00 PM ET
- Accepted
- Mar 18, 4:18 PM ET
- Size
- 20.2 KB